17.02.2016 • News

Ypso-Facto anticipates a solid growth in 2016

Ypso-Facto, a specialist in chemical and biochemical processes, announces today that for its first anniversary it has already gathered a 25-client portfolio mainly constituted of medium-sized companies and major international players. In 2015, over 50% of the company’s revenue was achieved outside of France and 2016 is expected to be very dynamic: “Our order book is in very good shape. We have secured excellent projects and we anticipate a solid growth. Our credo is the combination of scientific excellence and deep industrial knowledge. We will keep developing our offer through recruitment, partnerships or acquisitions.” says the company’s founder and CEO, Roger-Marc Nicoud (also founder of Novasep). 

Ypso-Facto was created in 2014 and currently consists of a team of 15 engineers and PhDs in chemistry, biochemistry and process engineering. It helps industrial firms to develop, optimize and secure their chemical and biochemical processes. It offers technical and scientific expertise, process simulation software and laboratory services. Soon after its creation, the company acquired SRT Expertise et Conseil (Lyon, France), a technical and TM scientific expertise provider founded by Serge Ratton. In summer 2015, ChromWork, a chromatographic process simulation software, was integrated and a US subsidiary was created in the Boston (MA) area. This already provides the company with an international span. Earlier in 2015, Ypso-Facto had been granted the Young Innovative Company label (Jeune Entreprise Innovante, J.E.I.)

Company

Ypso-Facto

Le Cardinal, 2-4 rue du Cardinal Tisserant
54 000 Nancy
France

Company contact







Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.